Diabetes is now considered an important risk factor for cardiovascular disease, and a complex interplay of pathogenic factors complicates management of both diseases.
ESC 2018 Although aspirin resulted in a reduction of CV events in a primary prevention setting of diabetes patients, this CV benefit was counterbalanced by an increase in bleeding.
ESC 2018 One large randomized trial showed that use of aspirin for primary prevention reduced CV events in a diabetes population but at the cost of bleeding, and another resulted in no CV benefit in individuals with moderate CV risk.
ESC 2018 In overweight or obese patients with CVD or diabetes with CV risk factors, lorcaserin demonstrated to be safe with respect to CV outcomes. Dr Bohula discussed the details of the CAMELLIA-TIMI 61 trial.
ESC 2018 Use of omega-3 fatty acid supplements did not result in reduction of CV outcomes in the ASCEND trial, a large, randomized, long-term trial of diabetes patients.
Multiple pathways play a role in the development of T2DM. This is why targeting multiple processes may improve glucose regulation. Prof. Bailey gives an extensive overview of the available therapeutic options, discussing mechanisms, advantages and disadvantages.
Download the meeting impression of this PACE symposium during Heart Failure 2018, which considered what recent outcome trials with glucose-lowering trials can tell us about us about optimal management of patients with HF and diabetes.
Prof. Sattar looked at the data of recent outcome trials to postulate how they might work to exert the observed clinical benefit. Altered hemodynamics likely importantly contribute to the benefits on HF outcomes.
Download the meeting impression of this PACE symposium during EuroPrevent 2018, that considered how to apply novel outcome data with GLP-1 RA to clinical practice.
This is a summary of the presentation by prof. Rydén, in which he reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.
This is a summary of presentation given by prof. Grobbee, in which he discusses how to reduce CV risk in patients with T2DM, considering the effects of glucose control and the effect of newer agents.
This summary of the presentation by prof. Hobbs illustrates why diabetes poses a high burden to primary health care, since patients with T2DM are at high CV risk. This risk can be lowered by targeting various risk factors.
Naveed Sattar summarizes the findings of the EMPA-REG Outcome trial, and what this tells us about potential mechanisms that led to the observed CV benefit with the SGTL2 inhibitor empagliflozin.